Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 20/20 | 0.66 |
| ▸ | CDK2 | P24941 | 20/20 | 0.66 |
| ▸ | CCNA1 | P78396 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792639 | 0.92 | CCNA2 (0.63) | CCNA2CDK2CCNA1 | |
| SCHEMBL6795093 | 0.91 | CCNA2 (0.71) | CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL6790434 | 0.90 | CCNA2 (0.70) | CCNA2CDK2CCNA1 | |
| SCHEMBL5229650 | 0.87 | CCNA2 (0.64) | CCNA2CDK2CCNA1 | |
| SCHEMBL5230731 | 0.87 | CCNA2 (0.73) | CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL6794168 | 0.86 | CCNA2 (0.61) | CCNA2CDK2CCNA1 | |
| SCHEMBL5229256 | 0.86 | CCNA2 (0.78) | CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL6797723 | 0.84 | CCNA2 (0.71) | CCNA2CDK2CCNA1 | |
| SCHEMBL5232538 | 0.84 | CCNA2 (0.66) | CCNA2CDK2CCNA1 | |
| SCHEMBL5229349 | 0.80 | CCNA2 (0.61) | CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | claimed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | claimed |
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | disclosed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | disclosed |
| EP-1478357-A2 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003070236-A2 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | TP53, NFATC1, MAP3K15 | CCNA2 1338/4885CDK2 178/4885CCNA1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.